S/MARter Immunotherapies
Platforms
selecTCR
Tcelltech has developed an AI-guided classifier which identifies tumor-targeting T cell receptors (TCRs) within days (see https://www.nature.com/articles/s41587-024-02161-y), immediately available for cell manufacturing.
A web-based tool @ http://predictcr.com allows for interrogating existing datasets. This platform not only identifies therapeutic T cell receptors but is also developed to detect T cell signatures for predicting and monitoring response to immunotherapies.
Our predicTCR has been validated in melanoma, colorectal, pancreatic, lung and brain cancer.
nanoSMAR
We have developed nanoSMAR, a novel, minimally-sized, episomal DNA vector platform which possesses an unlimited genetic cargo capacity and provides robust and persistent gene expression with minimal disruption to cell homeostasis. It is non-toxic and non-immunogenic.
Tcelltech has successfully demonstrated the efficacy of nanoSMAR in a diverse range of applications, including cell therapy, gene therapy, and regenerative medicine. From these data, nanoSMAR appears to be greatly superior to current viral vector-based strategies.
In 2026, nanoSMAR will undergo clinical validation in a TCR-mediated cell therapy trial.
We are actively looking for licensing partners for our nanoSMAR vector platform.